50 results on '"Huang, Qiu-Sha"'
Search Results
2. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
3. A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study
4. Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study
5. Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study.
6. Clinical features and prognostic model for viral encephalitis after allogeneic haematopoietic stem cell transplantation.
7. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP
8. Prognostic Factors and Outcomes in Patients With Septic Shock After Allogeneic Hematopoietic Stem Cell Transplantation
9. A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy
10. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial
11. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data
12. Prognostic factors and outcomes in patients with septic shock after allogeneic hematopoietic stem cell transplantation
13. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
14. Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation
15. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
16. Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation
17. S295: TACROLIMUS MODULATES CD4+ T-CELL PROLIFERATION AND FUNCTION VIA MTHFD2 IN IMMUNE THROMBOCYTOPENIA
18. P1277: IMPACT OF A NOVEL PROGNOSTIC MODEL ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH CMML
19. P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP
20. S290: DEVELOPMENT AND VALIDATION OF A PROGNOSTIC MODEL OF BRONCHIOLITIS OBLITERANS SYNDROME IN ADULT PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
21. PB2420: DEVELOPMENT AND VALIDATION OF THE PRACT MODEL FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS ABOVE 60 YEARS OLD WITH HAEMATOLOGICAL MALIGNANCIES IN A REAL-WORLD STUDY
22. P1591: IMPACT OF COVID-19 ON THE EVOLUTION OF PRE-EXISTING PRIMARY IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE OBSERVATIONAL STUDY
23. P1590: THE IFI27/TFEB PATHWAY MEDIATES THE IMPAIRED AUTOPHAGIC DEGRADATION OF ITP BONE MARROW MACROPHAGES, RESULTING IN IMPAIRED MEGAKARYOCYTE MATURATION IN ITP
24. P1533: A PROGNOSTIC MODEL FOR PATIENTS WITH SEPTIC SHOCK AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
25. P1594: BARICITINIB FOR STEROID-RESISTANT/RELAPSE IMMUNE THROMBOCYTOPENIA (BAITP): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL
26. S296: IL-1Β SIGNALLING INDUCES, AND BARICITINIB ALLEVIATES NEU1-MEDIATED MEGAKARYOCYTE DESIALYLATION IN IMMUNE THROMBOCYTOPENIA
27. Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients withCMML
28. sj-docx-7-tah-10.1177_20406207221095226 – Supplemental material for Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
29. sj-docx-1-tah-10.1177_20406207221095226 – Supplemental material for Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
30. Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
31. All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP
32. Machine-Learning Model for Resistance/Relapse Prediction in Immune Thrombocytopenia Using Gut Microbiota and Function Signatures
33. Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET 020)
34. High Dimensional Single-Cell Profiling Identifies Immune and Metabolic Heterogeneity in Immune Thrombocytopenia
35. Evaluation of ISTH Severe Bleeding Criteria and Development of a Mortality Prognosis Model for Hospitalized Immune Thrombocytopenia Patients: A Multicenter, Retrospective and Prospective Cohort Study
36. Projected Global Trends in Hematological Malignancies: Incidence, Mortality, and Disability-Adjusted Life Years from 2020 to 2030
37. Baricitinib in Combination with High-Dose Dexamethasone As First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial
38. Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study
39. A New Prognostic Scoring System (BRIGHT) Predicts Mortality of Septic Shock after Allogeneic Hematopoietic Stem Cell Transplantation
40. Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR+ and αvβ3+ Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT
41. Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age
42. Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative data
43. ATRA Could Correct the Defective S1P-Mediated Cytoskeletal Reorganization in Proplatelet Formation of ITP
44. Combination of ATRA and High-Dose Dexamethasone As First-Line Treatment in Adult Immune Thrombocytopenia:a Randomized, Phase 2, Open-Label Trial
45. All-transretinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP
46. Arsenic Trioxide Encapsulated in MSC-Derived Extracellular Vesicles: A Novel Therapy for aGVHD in Mice
47. Overexpression of WT1and PRAMEpredicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
48. Tacrolimus and Danazol Combination As a Second-Line Therapeutic Strategy for Steroid-Resistant or Relapsed Immune Thrombocytopenia: A Prospective, Randomized, Multicenter, Open-Label Study
49. Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR+and αvβ3+Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT
50. Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.